MarjorieGreenMD

Breast Cancer, Hematologic Oncology

SVP, Late Stage Clinical Development

Dr. Green is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 1998 - 2001
University of Virginia Medical CenterResidency, Internal Medicine, 1995 - 1998
University of Texas Medical Branch School of MedicineClass of 1995

Seagen Announces U.S. FDA Approval of New Indication for ADCETRIS® (Brentuximab Vedotin) for Children with Previously Untreated High Risk Hodgkin LymphomaNovember 10th, 2022
ADCETRIS® (Brentuximab Vedotin) plus Standard of Care Chemotherapy Demonstrates Superior Event-Free Survival (EFS) vs. Standard of Care Alone in Children and Young Adults with Previously Untreated High-Risk Hodgkin LymphomaJune 3rd, 2022
Seagen and Astellas Announce Initial Results of PADCEV® (Enfortumab Vedotin-Ejfv) in Patients with Muscle-Invasive Bladder Cancer Not Eligible for Cisplatin ChemotherapyFebruary 14th, 2022
Join now to see all